Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 183 participants.

Also called NCT01288443

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 183 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01288443
Main results
  • Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy Journal of the American College of Cardiology, 2012-06-19 DOI, PubMed 22463922
Other papers using this trial's data
  • Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy Journal of the American Heart Association, 2015-11-19 DOI, PubMed 26586732, PMC4845239 In the PMC Open Access subset under CC BY-NC.
  • Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials) The American journal of cardiology, 2014-09-01 DOI, PubMed 25060413

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01288443. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2015-09-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
Condition
Hypercholesterolemia
Intervention (Drug)
Alirocumab
Intervention (Drug)
Placebo (for alirocumab)
Intervention (Drug)
Atorvastatin
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01288443
Content hash
b20ccdae9ec4b1597c4b638f4e331bfe8d7d06b1b1aa02cfa959828ad0475a42